ClinicalTrials.gg
CompletedNCT04990310Updated Nov 24, 2021

Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Healthy Male Participants

A Phase 1 interventional study of [14C]-CORT113176 in Healthy, sponsored by Corcept Therapeutics. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-24.

Sponsored by Corcept Therapeutics · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
30 Years to 65 Years
Sex
Male
01

Study summary

This study will evaluate the mass balance recovery and metabolite profile, and will identify metabolite structures following a single oral dose of [14C]-CORT113176 in healthy male participants.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Corcept Therapeutics is the lead sponsor of 73 studies on the registry; 3 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 9 (28%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18.0 to 30.0 kg/m\^2, inclusive
  • Willing and able to participate in the whole study
  • Have regular bowel movements (i.e., average stool production of ≥1 and ≤3 stools per day)
  • Provide written
  • Adhere to the requirements.

Exclusion criteria

Exclusion Criteria:

  • Have received any medicine in a clinical research study within 90 days
  • Are, or are immediate family members of, a study site or sponsor employee
  • Evidence of current severe acute respiratory syndrome (SARS-CoV-2) infection
  • History of any drug or alcohol abuse, or regularly consume >21 units alcohol per week
  • Current smoker or user of e-cigarettes and nicotine replacement products within the last 6 months
  • Have pregnant or lactating partners
  • Radiation exposure, exceeding 5 milliSieverts (mSv) in the last 12 months or 10 mSv in the last 5 years
  • abnormal results of clinical chemistry, hematology or urinalysis as judged by the investigator
  • Confirmed positive drugs of abuse test result
  • Positive surface antigen (HBsAg), virus antibody (HCV Ab) or (HIV) antibody results
  • Active renal and/or hepatic disease
  • History of clinically significant cardiovascular, renal, hepatic, dermatological, chronic respiratory or gastrointestinal (GI) disease, neurological or psychiatric disorder
  • Any form of cancer within the last 5 years (exceptions apply)
  • History and/or symptoms of adrenal insufficiency
  • Condition that could be aggravated by antagonism or activation
  • Donation of blood or plasma or loss of greater than 400 mL of blood within the previous 3 months
  • Are taking, or have taken, any prescribed or over-the-counter drug or herbal remedies (other than up to 4 g of paracetamol per day) within 14 days. COVID-19 vaccines are accepted concomitant medications. Exceptions may apply on a case by case basis.
  • Currently using glucocorticoids or have a history of systemic glucocorticoid use at any dose within the last 12 months or 3 months for inhaled products
  • Additional criteria apply.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Study Participants

    On Day 1, participants will receive a single oral dose of \[14C\]-CORT113176 450 mg (3 X 150 mg lipid formulation capsules) in the fed state.

    Drug: [14C]-CORT113176

Interventions

  • \[14C\]-CORT113176 450 mg lipid formulation capsule for oral administration containing not more than 3.37 megaBequerel 14C.

06

What researchers measure

Primary outcomes

  1. Mass Balance Recovery in Excreta After a Single Dose of [14C]-CORT113176

    Time frame: Until the mass balance criteria for all participants have been met (estimated up to 28 days)

Secondary outcomes

  1. Mass Balance Recovery in Urine After a Single Oral Dose of [14C]-CORT113176

    Time frame: Until the mass balance criteria for all participants have been met (estimated up to 28 days)

  2. Mass Balance Recovery in Feces After a Single Oral Dose of [14C]-CORT113176

    Time frame: Until the mass balance criteria for all participants have been met (estimated up to 28 days)

  3. Number of CORT113176 Metabolites Accounting for ≥10% of Total Circulating Radioactivity or ≥10% of Dose Excreted in Urine and Feces

    Time frame: Until the mass balance criteria for all participants have been met (estimated up to 28 days)

  4. Plasma Pharmacokinetics (PK) of Total Radioactivity after Oral Dosing: Peak Plasma Concentration (Cmax)

    Time frame: Before dosing and at pre-specified time points up to Day 8 after dosing

  5. Plasma PK of Total Radioactivity after Oral Dosing: Time from Dosing to Cmax (Tmax)

    Time frame: Before dosing and at pre-specified time points up to Day 8 after dosing

  6. Plasma PK of Total Radioactivity after Oral Dosing: Area Under the Plasma Concentration-time Curve from Zero Time to Time of the Last Measurable Concentration (AUC0-last)

    Time frame: Before dosing and at pre-specified time points up to Day 8 after dosing

  7. Plasma PK of Total Radioactivity after Oral Dosing: Apparent Elimination Half-life (t1/2)

    Time frame: Before dosing and at pre-specified time points up to Day 8 after dosing

  8. Plasma PK of CORT113176 after Oral Dosing: Cmax

    Time frame: Before dosing and at pre-specified time points up to Day 8 after dosing

  9. Plasma PK of CORT113176 after Oral Dosing: Tmax

    Time frame: Before dosing and at pre-specified time points up to Day 8 after dosing

  10. Plasma PK of CORT113176 after Oral Dosing: AUC0-last

    Time frame: Before dosing and at pre-specified time points up to Day 8 after dosing

  11. Plasma PK of CORT113176 after Oral Dosing: t1/2

    Time frame: Before dosing and at pre-specified time points up to Day 8 after dosing

  12. Distribution of Total Radioactivity into Red Blood Cells after Oral Dosing

    Time frame: Before dosing and at pre-specified time points up to Day 8 after dosing

  13. Number of Participants with One or More Adverse Events

    Time frame: Until the mass balance criteria for all participants have been met (estimated up to 28 days)

07

Study locations

1 site
  • Site 01
    Ruddington, Nottingham NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Sep 2021, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2021
First posted
Aug 4, 2021
StartActual
Aug 18, 2021
Primary completionActual
Sep 20, 2021
CompletionActual
Sep 20, 2021
Last update
Nov 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04990310
Responsible party
Sponsor
First posted
Aug 4, 2021
Start date
Aug 18, 2021
Primary completion
Sep 20, 2021
Completion
Sep 20, 2021
Last update
Nov 24, 2021

Study contacts

Hazel Hunt, Ph.D.
study director · Corcept Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CORT113176

Start the discussion